drugset / Trial / NCT03778073
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Timeline
- Start
- 2019-04-17
- Primary completion
- 2022-05-03
- Completion
- 2022-08-01
Outcome
Outcome not reported
Stopped (Business): “Strategic/Business Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | — | Intravenous |
| Subject | Cosibelimab | Monoclonal antibody | — | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |